R&D Pipeline and Funding

Global Health and Pandemic Preparedness

Supported almost exclusively by non-dilutive funding, Aldatu has received $16M from the National Institute of Allergy and Infectious Diseases [NIAID] to advance diagnostics using our PANDAA technology platform.

R&D Pipeline and Funding

Global Health and Pandemic Prevention, Preparedness and Response

Supported almost exclusively by non-dilutive funding, Aldatu has received $16M from the National Institute of Allergy and Infectious Diseases [NIAID] to advance diagnostics using our PANDAA technology platform.

HIV Drug Resistance Genotyping

ReFocus I

$1.5M NIAID SBIR

Detects six drug resistance mutations (DRMs) in >99% of HIV-infected patients failing first-line antiretroviral treatment (ART).
Genotypes 24 patients in <20 hours.

Available as RUO product: aldatubio.com/product/pandaa-qdx-hivdr-rti/

ReFocus II

$3M NIAID SBIR

$3M NIAID Commercialization

Detects eight DRMs in HIV-infected patients failing protease inhibitor second-line antiretroviral treatment (ART).  Genotypes 20 patients in <2 hours.

ExPAND

$3.3M NIAID Contract

Detects low-level DRM variants at 1% for all HIV antiretroviral drug classes.

ReFocus I

$1.5M NIAID SBIR

Detects six drug resistance mutations (DRMs) in >99% of HIV-infected patients failing first-line antiretroviral treatment (ART). Genotypes 24 patients in <20 hours.

Available as RUO product: aldatubio.com/product/pandaa-qdx-hivdr-rti/

ReFocus II

$3M NIAID SBIR

$3M NIAID Commercialization

Detects eight DRMs in HIV-infected patients failing protease inhibitor second-line antiretroviral treatment (ART).  Genotypes 20 patients in <2 hours.

ExPAND

$3.3M NIAID Contract

Detects low-level DRM variants at 1% for all HIV antiretroviral drug classes.

Pandemic Preparedness

Viral Hemorrhagic Fevers

Pandemic Preparedness - Viral Hemorrhagic Fevers

Lassa fever

$300K NIAID SBIR

The first pan-lineage real-time PCR assay for the qualitative detection of Lassa virus (LASV) RNA.

  • The only assay for universal pan-lineage detection of the Lassa virus – detects all lineages of LASV with equal sensitivity
  • Fast – delivers accurate results from RNA in 1 hour
  • One of the most sensitive LASV molecular diagnostics available, with a limit of detection 10 copies / reaction.


    Available as an RUO product:
    aldatubio.com/product/pandaa-qdx-lasv

Lassa fever

$300K NIAID SBIR

The first pan-lineage real-time PCR assay for the qualitative detection of Lassa virus (LASV) RNA.

  • The only assay for universal pan-lineage detection of the Lassa virus – detects all lineages of LASV with equal sensitivity
  • Fast – delivers accurate results from RNA in 1 hour
  • One of the most sensitive LASV molecular diagnostics available, with a limit of detection 10 copies / reaction.


    Available as an RUO product:
    aldatubio.com/product/pandaa-qdx-lasv

Crimean-Congo hemorrhagic fever

$2M NIAID SBIR

The first universal, pan-clade CCHFV diagnostic.

  • The first CCHFV diagnostic that meets the WHO R&D blueprint target product profile
  • The only assay that can detect all CCHFV clades, and with equal sensitivity
  • Fast – delivers accurate results from RNA in 1 hour
  • A limit of detection 10 copies / reaction.

Ebola and Marburg​

$3M NIAID SBIR

Under development to detect all species of Ebolavirus and differentiation with Marburgvirus.

  • Detect and differentiate Ebolavirus from Marburgvirus.
  • Detect all six species of Ebolavirus with equal sensitivity. 

Crimean-Congo hemorrhagic fever

$2M NIAID SBIR

The first universal, pan-clade CCHFV diagnostic.

  • The first CCHFV diagnostic that meets the WHO R&D blueprint target product profile
  • The only assay that can detect all CCHFV clades, and with equal sensitivity
  • Fast – delivers accurate results from RNA in 1 hour
  • A limit of detection 10 copies / reaction.

Ebola and Marburg​

$3M NIAID SBIR

Under development to detect all species of Ebolavirus and differentiation with Marburgvirus.

  • Detect and differentiate Ebolavirus from Marburgvirus.
  • Detect all six species of Ebolavirus with equal sensitivity.